Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects
about
Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.Neratinib (HKI-272) in the treatment of breast cancer.The role of neratinib in HER2-driven breast cancer.Neratinib for the treatment of HER2-positive early stage breast cancer.Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Targeted Covalent Inhibitors for Drug Design.Neratinib for the treatment of breast cancer.The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.Drug-drug interactions--bridging the gulf between the bench and the bedside?LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.Neratinib: First Global Approval.Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.An eco-friendly direct spectrofluorimetric method for the determination of irreversible tyrosine kinase inhibitors, neratinib and pelitinib: application to stability studies.Raman Micro-Spectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells.
P2860
Q34511634-AD7299D7-A86F-45BE-A202-C01432447E63Q35914446-2F2D9A6D-1FB0-4FFB-8BC5-446177E936D6Q36057369-5F7EB961-F182-400E-BA96-2A79E070B1FEQ38024121-CC972575-13CD-4EB8-AD9E-EA34BE33B749Q38664492-BACD4CE9-D212-4604-AC71-8D980F4CE424Q38666768-BFD95E25-481B-454E-A7B4-E726582459EAQ38718320-7FECD6F5-FEF2-49F4-93AA-E7698BEE0D95Q38861026-93EE23FF-95F9-4837-9614-09592B6501B6Q38931379-A2F70E29-6B86-42A6-BE70-B0821A134ADDQ39333848-9009C70C-25A1-4655-95DF-4FB59A048412Q39682085-B908D857-BAB0-4990-A3D1-154463ED13BCQ42720500-88AED520-7DA6-4F7D-B2D8-F87AA89EFF1EQ49530239-8E536EC5-30FD-49A6-AEBB-3D20C85F7751Q50201250-27C78EF4-FBEE-4EBF-894A-BCA6B546A4FBQ51026212-58FE7FA5-3CF8-4224-B508-5EAD6C788A9AQ51129728-FCB57717-CE24-40B6-8ED2-8920D221EA35Q51727547-D9899DCD-CFA3-4552-9894-E98D6D03E0F8Q52592302-CCD99CC1-22BC-4A97-AFE1-363E39F4B081
P2860
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@ast
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@en
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@nl
type
label
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@ast
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@en
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@nl
prefLabel
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@ast
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@en
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@nl
P2093
P2860
P1476
Pharmacokinetics of oral nerat ...... toconazole in healthy subjects
@en
P2093
Bruce A Hug
Cathie Leister
Daryl Sonnichsen
Jaime Burns
Richat Abbas
P2860
P304
P356
10.1111/J.1365-2125.2010.03845.X
P407
P577
2011-04-01T00:00:00Z